Isto Biologics, a portfolio company of Thompson Street Capital Partners and a provider of regeneration technologies, has acquired TheraCell.

TheraCell is focused on developing advanced technologies for bone and soft tissue repair and invented TheraFuze DBF demineralized bone fiber technology. Isto Biologics is a biologic and cellular therapy company in the orthopedic space and offers services for bone regeneration and cell-based therapies.

“Isto is the leader in spine solutions. They have an incredible patient-centric, outcomes-focused commercial and clinical team that will rapidly accelerate the surgical adoption of the technology that we’ve always been passionate about,” added Bradley Patt, CEO of TheraCell.